Jing, W., Ma, J., & Han, C. (2020). Metastatic Breast Cancer Coexisting With HER-2 Amplification and EGFR Exon 19 Deletion Benefits From EGFR-TKI Therapy: A Case Report. Front Oncol.
Chicago-stil citatJing, Wei, Jie-Tao Ma, och Cheng-Bo Han. "Metastatic Breast Cancer Coexisting With HER-2 Amplification and EGFR Exon 19 Deletion Benefits From EGFR-TKI Therapy: A Case Report." Front Oncol 2020.
MLA-referensJing, Wei, Jie-Tao Ma, och Cheng-Bo Han. "Metastatic Breast Cancer Coexisting With HER-2 Amplification and EGFR Exon 19 Deletion Benefits From EGFR-TKI Therapy: A Case Report." Front Oncol 2020.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.